Biography:

One of their most recent publications is Cyclosporine therapy for psoriasis: A cell cycle-derived dosing schedule***. Which was published in journal Journal of the American Academy of Dermatology.

More information about Matthew M. Goodman research including statistics on their citations can be found on their Copernicus Academic profile page.

Matthew M. Goodman's Articles: (2)

Cyclosporine therapy for psoriasis: A cell cycle-derived dosing schedule***

AbstractBackground: Cyclosporine is effective in the treatment of psoriasis; however, potentially serious side effects limit its long-term use. On the basis of the 36-hour psoriatic keratinocyte cell cycle, a new dosing regimen was investigated.Objective: The purpose of this study was to evaluate a 36-hour weekly dosing schedule with cyclosporine for the treatment of psoriasis, in an attempt to decrease side effects while maintaining efficacy.Methods: Fifteen patients were studied by means of oral doses of cyclosporine taken at 12-hour intervals for three doses per week during a 10-week period. The initial dose, 2.5 mg/ kg/dose (7.5 mg/kg/wk), was increased every 2 weeks by 2.5 mg/kg/dose to a maximum of 10 mg/kg/dose.Results: The average improvement as assessed by the Psoriasis Area and Severity Index for all 15 patients was 61%. Six patients had a more than 75% improvement, three patients improved 50% to 74%, and six patients improved less than 50%. Three patients dropped out because of adverse side effects, and three others completed the study at a reduced dose.Conclusion: It is concluded that, although effective, this dosing regimen may not have an advantage over daily dosing, given its side effect profile and the need to go to relatively high doses every 24 hours.

Original ArticleA Model of Human Melanoma in Cyclosporine-Immunosuppressed Rats

A human malignant melanoma maintained in athymic nude mice has been successfully implanted and grown in cyclosporine (Cys-)immunosuppressed Lewis rats. Suspended melanoma cells (106) or solid tumor sections measuring 2–4 mm in diameter were implanted s.c. in rats receiving parenteral Cys doses of 15–50 mg/kg each day for 1 weeks, and 3 times per week thereafter. Eighty-five percent of solid tumor section implanted in animals receiving 25 mg/kg resulted in tumor growth, whereas no tumors grew from cell suspension injection sites. The average maximum tumor growth rate was 2 cm3/day, with a doubling time of 8 days. Tumors retained pretransplant gross and microscopic morphology, karyotype, and labeling index. Possible advantages of this model over the athymic nude mouse include greater longevity, larger animal and tumor size, and less stringent aseptic environmental requirements. This model may prove useful for further study of the pathophysiology of melanoma and for testing of new antimelanoma therapies.

Advertisement
Join Copernicus Academic and get access to over 12 million papers authored by 7+ million academics.
Join for free!

Contact us